Development of a novel therapy for the treatment of epidermal squamous cell carcinoma

开发治疗表皮鳞状细胞癌的新疗法

• 批准号: nhmrc : 301075
• 负责人: A/Pr Nicholas Saunders
• 金额: $ 28.86万
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Project Grants
• 财政年份: 2004
• 资助国家: 澳大利亚
• 起止时间: 2004-01-01 至 2006-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/development-novel-therapy-cell-carcinoma/95939
• 关键词: Development; novel; therapy; treatment; epidermal

Squamous cell carcinomas (SCC) are the most common life-threatening form of skin cancer in Australia. SCCs commonly arise in areas of the body that have been exposed to excessive amounts of UV irradiation. The cells of the skin from which SCCs are derived are called keratinocytes. UV irradiation causes lesions within these cells such that their growth and maturation are disrupted leading to deregulated growth and maturation and hence tumour formation. We have previously identified a protein, E2F, that is central to this process and whose inhibition leads to decreased cancer cell growth. During the course of these studies we noted that the deregulation of E2F could also lead to the disruption of keratinocyte maturation. This led us to propose that the inhibition of E2F in SCCs may result in both decreased cancer cell growth as well as the reinstatement of a normal maturation process. this would make E2F inhibitors a very attractive therapeutic for treating SCC. In the present study we aim to explore the ability and the mechanism by which E2F modulates keratinocyte proliferation and maturation. This will be done in vitro as well as in animal models of SCC. These studies will be required in order to take the E2F inhibitors into clinical trials.

鳞状细胞癌（SCC）是澳大利亚最常见的危及生命的皮肤癌。SCC通常出现在暴露于过量紫外线照射的身体区域。SCC所来源的皮肤细胞被称为角质形成细胞。UV照射导致这些细胞内的损伤，使得它们的生长和成熟被破坏，导致生长和成熟失调，从而形成肿瘤。我们以前已经确定了一种蛋白质E2F，它是这一过程的核心，其抑制导致癌细胞生长减少。在这些研究的过程中，我们注意到E2F的失调也可能导致角质形成细胞成熟的破坏。这使我们提出，SCC中E2F的抑制可能导致癌细胞生长减少以及正常成熟过程的恢复。这将使E2F抑制剂成为治疗SCC的非常有吸引力的治疗剂。本研究旨在探讨E2F调控角质形成细胞增殖和成熟的能力及其机制。这将在体外以及SCC动物模型中进行。这些研究将需要E2F抑制剂进入临床试验。